Clinical Trials | A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

The University of Virginia seeks adult women ages 18 years and older with high grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who’s cancer has relapsed after previous platinum-based chemotherapy. The goal of this study is to test the efficacy and safety of an investigational medication called Raludotatug deruxtecan (R-DXd), which is an antibody-drug conjugate (ADC), when taken along with standard cancer treatments. ADCs attach to a protein on cancer cells, delivering treatment directly to destroy them. Researchers want to see if R-DXd works well with the standard treatment and if people can tolerate both treatments together. You may be eligible for this study if: - You have high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube - Your cancer has relapsed after 1-3 previous cancer therapies This study involves blood sampling, eye exam, physical examination, imaging of the chest, abdomen and pelvis, an echocardiogram (ECHO), and an electrocardiogram (ECG). Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT06843447